Editorial: potassium-competitive acid blockers for acid-related diseases-tegoprazan, a new kid on the block

The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease

(2019) Carmelo Scarpignato et al.   CURRENT OPINION IN GASTROENTEROLOGY

Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects

(2019) Sungpil Han et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects

(2018) J. Sunwoo et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Update on the Use of Vonoprazan: A Competitive Acid Blocker

(2018) David Y. Graham et al.   GASTROENTEROLOGY

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

No Acid, No Ulcer: Dragutin (Carl) Schwarz (1868–1917), the Man Ahead of His Time

(2011) Stella Fatović-Ferenčić et al.   DIGESTIVE DISEASES

Clinical trial: Inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects

(2010) Hyung-Keun Kim et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY